Work

Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.2587

Authors: Naoko Takebe, Geraldine Helen O'Sullivan Coyne, Shivaani Kummar, Khanh Tu Do, Ashley Bruns, Lamin Juwara, Mary Flanagan Quinn, Lyndsay Harris, Richard Piekarz, Sheila Ann Prindiville, Elad Sharon, Howard Streicher, Ganesh Mugundu, Jiuping Jay Ji, Deborah Wilsker, Robert J. Kinders, Larry Rubinstein, James H. Doroshow, Alice P. Chen

Institutions: National Institutes of Health, National Cancer Institute, Pfizer (United States), Frederick National Laboratory for Cancer Research, Center for Cancer Research

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891028694

Cites:

Cited by: 8

Related to: 10